TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maintenance in rhythm control strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Single Negative PCR Result and 3 Negative Culture Assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Distribution of IgG subclasses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hot Flash Severity Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of plasma lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variation of fecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Variation of antioxidant activity on fecal waters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Vital Signs - Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence or absence of shunt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in Prefrontal cortex brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: occurrence of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Level of Alpha Melanocyte Stimulating Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: dMRT changes during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparability to gold standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Working memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Response to TNF inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate of CyberKnife body radiosurgery
Endpoint domain: Adverse events/effects
Primary endpoint: Venous segment occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Scores on the MGH-CPFQ
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Scores on the MGH-CPFQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Severe Covid-19
Endpoint domain: Mortality/survival
Primary endpoint: Severe Covid-19 with pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Disease Progression at Week 240
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of post spinal hypotension (PSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Complete Response (CCR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Auditory Hallucination Rating Scale (AHRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 30-Day Major Adverse Cardiovascular Events
Endpoint domain: Adverse events/effects
Primary endpoint: Nature, frequency, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of central subfield thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in unresolved aches and discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Berg balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: National Institute of Health stroke scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to expression of the ON state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Continuous time of the ON state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: HPV infection prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Identification of HPV circulating strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient sedation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catestatin levels in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of pain during IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Part/Whole Identity Test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reading the Mind in the Eyes Task scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of AIC measured by EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regular intake of Oral Rehydration Solution (ORS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Two minute Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grades 3-5 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Weight Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Height Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Bone Mineral Density (BMD) Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Perceived improvement in voiding condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NIRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin blood flow variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: time to first occurrence of Cmax (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-recovery relapse cases
Endpoint domain: Adverse events/effects
Primary endpoint: Serial Postoperative HgA1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Device related Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs (blood pressure, heart rate, ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical laboratory assessments (standard laboratory parameters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSV detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical Efficacy Rated by the Patient or Caregiver
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of the Clinical Efficacy Rated by a Study Physician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological Improvement Measured by Confocal Microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rostral fluid shift during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sustained clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Curve for the Number of Oral Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological Response at Test-of-Cure Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: treatment initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance of automated EF and GLS measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anti-neuronal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first confirmed occurrence of Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of suicide risk
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: qNOX change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Durvalumab plus Tremelimumab
Endpoint domain: Adverse events/effects
Primary endpoint: AUC inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stony Brook Scar Evaluation Scale (SBSES) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety and tolerability as measured by adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative number of primary composite events of cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Total HF hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disorders of heart rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum concentration (Cmax) of Estetrol in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) from time zero to the last determinable concentration of Estetrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of Estetrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of awareness or inadequate anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Vasodilator Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Functional Capacity - Distance Walked in 6 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Any Unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 & 4 PSN
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Women Pre-Screened Who Have an EPDS Score >/= 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response post dose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alteration of left ventricular myocardial strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Haller index (HI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of POCE
Endpoint domain: Mortality/survival
Primary endpoint: Amount of uric acid excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effect on blood level of drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in number of gas evacuations per anus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in intestinal gas volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gas related symptoms (self-completed questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Body Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Systolic and Diastolic Blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Closure of tracheobronchial fistulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Newly Active Lesions in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of participants admitted to the intensive care unit that requires simultaneous insertion of endotracheal tube, central venous catheter and urinary catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility - Occurrence of sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: COVID19 positive cases
Endpoint domain: Mortality/survival
Primary endpoint: COVID19 hospital admissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Deaths due to COVID19
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with Complete Remission (CR) or CR with incomplete blood count recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Score of Relationship Functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percent Days Heavy Drinking
Endpoint domain: Adverse events/effects
Primary endpoint: Anatomical coverage during OGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-to-wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Infants That Developed Dolichocephaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Activity Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minute Walks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance change after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease the risk of local and distant tumor growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Percent Drinking Days (PDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent Heavy Drinking Days (PHDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients in success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Endurance walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle mass index (SMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in striae roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in average Melanin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in melanin variation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gait Components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUCt) of raloxifene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of raloxifene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt, corr of cholecalciferol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax, corr of cholecalciferol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of cytopenias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Angina Pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypercholesterolemia or Familial Hypercholesterolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Total Body Weight Loss (% TBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Local and systemic tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Who Discussed Disease Risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma oxylipin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of hypoxia in tumor nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connors' Adult ADHD Rating Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact Lens Wearing Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Donor Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen Induced Aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose values of 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quantification of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dose Limiting Toxicity (DLT) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sucking activity of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in performance of Physical fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Balance and walking ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of osteoblastic bone lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perceived Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Gait Related Relapse Indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood cell transcriptome/gene-expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in disease activity assessed by CDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Admission length
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Need of ICU stay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Severity of Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Cataract Development or Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased progression of diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: cumulative delivery rate
Endpoint domain: Mortality/survival
Primary endpoint: Early growth of Lactobacilli in stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Quality of Life (QOL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intrathoracic blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global enddiastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emotional functioning/wellbeing
Endpoint domain: Life impact
Primary endpoint: Change in Cortical Porosity (Ct.Po) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Migraine Specific Quality of Life - Restrictive
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Migraine Specific Quality of Life - Preventive
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Migraine Specific Quality of Life - Emotional
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Major gastrointestinal adjuvant prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes